Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Trial details
- Registry ID
- NCT04629703
- Drugs studied
- Fostamatinib
TrialRedline tracks 3 clinical trials sponsored by Rigel Pharmaceuticals: 2 Phase 3, 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 SubjectsNCT04629703 | Fostamatinib | Completed | 2022-09-05Actual |
| Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)NCT02077192 | Fostamatinib Disodium | Completed | 2020-06-02Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of Olutasidenib and Temozolomide in HGGNCT06161974 | Olutasidenib + TMZ | Recruiting | 2029-06Estimated |
Names as written in the registry records.